Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review - PubMed (original) (raw)
Case Reports
doi: 10.1016/j.autrev.2008.07.034. Epub 2008 Aug 19.
Affiliations
- PMID: 18718560
- DOI: 10.1016/j.autrev.2008.07.034
Free article
Case Reports
Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review
Leonardo Punzi et al. Autoimmun Rev. 2009 Jan.
Free article
Abstract
Blau syndrome (BS) is a rare familial disease transmitted as an autosomal dominant trait, characterized by arthritis, uveitis, skin rash and granulomatous inflammation. Until now BS has been observed in 136 persons belonging to 28 families as well as in 4 sporadic cases. The gene responsible for BS has recently been identified in the nucleotide-binding domain (NBD) of caspase recruitment domain (CARD15/NOD2), also involved in the pathogenesis of Crohn's disease. In addition to three missense mutations (R334Q, R334W and L469F) previously identified, a new CARD 15 mutation (E383K) has recently been described in a family followed by us for the past 25 years. The characteristics of this family which, to our knowledge, is the only one affected with BS in Italy, are the object of this manuscript. Both the proband and her daughter were originally affected with a papulonodular skin eruption and then with mild arthritis of the hands and feet. The proband, but not the daughter, complained of severe chronic bilateral uveitis, followed by glaucoma and, a few years later, by cataracts. Histological examination of skin biopsies from both subjects and a joint biopsy (daughter only), showed non-caseating granulomas with multinucleated giant cells which, at electron microscopy, revealed "comma-shaped bodies" in epithelioid cells, thought to be a marker for BS. The disease is presently well controlled with low doses of prednisone for the mother and non-steroidal anti-inflammatory drugs (NSAIDs) plus low doses of prednisone, when necessary, for the daughter. As in Crohn's disease, CARD15/NOD2 mutation is believed to be responsible for the granulomatous autoinflammatory reactions probably triggered by microorganisms in BS.
Similar articles
- A new CARD15 mutation in Blau syndrome.
van Duist MM, Albrecht M, Podswiadek M, Giachino D, Lengauer T, Punzi L, De Marchi M. van Duist MM, et al. Eur J Hum Genet. 2005 Jun;13(6):742-7. doi: 10.1038/sj.ejhg.5201404. Eur J Hum Genet. 2005. PMID: 15812565 - Blau syndrome associated with a CARD15/NOD2 mutation.
Snyers B, Dahan K. Snyers B, et al. Am J Ophthalmol. 2006 Dec;142(6):1089-92. doi: 10.1016/j.ajo.2006.06.064. Epub 2006 Aug 2. Am J Ophthalmol. 2006. PMID: 17157607 - CARD15 mutations in Blau syndrome.
Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, Chamaillard M, Zouali H, Thomas G, Hugot JP. Miceli-Richard C, et al. Nat Genet. 2001 Sep;29(1):19-20. doi: 10.1038/ng720. Nat Genet. 2001. PMID: 11528384 - Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation.
Kurokawa T, Kikuchi T, Ohta K, Imai H, Yoshimura N. Kurokawa T, et al. Ophthalmology. 2003 Oct;110(10):2040-4. doi: 10.1016/S0161-6420(03)00717-6. Ophthalmology. 2003. PMID: 14522785 Review. - Blau syndrome, clinical and genetic aspects.
Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L. Sfriso P, et al. Autoimmun Rev. 2012 Nov;12(1):44-51. doi: 10.1016/j.autrev.2012.07.028. Epub 2012 Aug 2. Autoimmun Rev. 2012. PMID: 22884558 Review.
Cited by
- Proteomic Profiling of Tears in Blau Syndrome Patients in Identification of Potential Disease Biomarkers.
Galozzi P, Bindoli S, Baggio C, Battisti I, Leonardi A, Basso D, Arrigoni G, Sfriso P. Galozzi P, et al. Int J Mol Sci. 2024 Aug 1;25(15):8387. doi: 10.3390/ijms25158387. Int J Mol Sci. 2024. PMID: 39125957 Free PMC article. - Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report.
Saigal K, Maleki A. Saigal K, et al. Case Rep Ophthalmol. 2024 Jan 19;15(1):63-70. doi: 10.1159/000535984. eCollection 2024 Jan-Dec. Case Rep Ophthalmol. 2024. PMID: 38250196 Free PMC article. - Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.
Matsuda T, Kambe N, Takimoto-Ito R, Ueki Y, Nakamizo S, Saito MK, Takei S, Kanazawa N. Matsuda T, et al. Front Immunol. 2022 May 27;13:895765. doi: 10.3389/fimmu.2022.895765. eCollection 2022. Front Immunol. 2022. PMID: 35711422 Free PMC article. Review. - _NOD_2 Mutation-Associated Case with Blau Syndrome Triggered by BCG Vaccination.
Arakawa A, Kambe N, Nishikomori R, Tanabe A, Ueda M, Nishigori C, Miyachi Y, Kanazawa N. Arakawa A, et al. Children (Basel). 2021 Feb 6;8(2):117. doi: 10.3390/children8020117. Children (Basel). 2021. PMID: 33562038 Free PMC article. - Neurological Manifestations of Primary Immunodeficiencies.
Chavoshzadeh Z, Hashemitari A, Darougar S. Chavoshzadeh Z, et al. Iran J Child Neurol. 2018 Summer;12(3):7-23. Iran J Child Neurol. 2018. PMID: 30026765 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous